

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-873

PHARMACOLOGY REVIEW(S)

Pharmacology/Toxicology Review

Date: 5-17-06

NDA #: 21-873

Date of submission: 3-1-06

Sponsor: Berlex Laboratories, Inc.

Drug Product: YAZ (Drospirenone 3 mg/ethinylestradiol 0.02 mg tablets)

Indication: Premenopausal dysphoric disorder (PMDD)

Subject: Class 1 Resubmission. P/T prospective about the approval of the NDA

NDA 21-873 originally submitted on 12-22-04 was reviewed on 2-24-05. All pharmacology, ADME, general toxicology, genotoxicity studies, reproductive toxicity studies and carcinogenicity studies reviewed under NDA 21-098 for the approval of Yasmin supported the safety of combination of drospirenone/ethinyl estradiol for the contraception indication. The primary difference between Yasmin and Yasmin 20 (YAZ) is that the reduced amount of ethinyl estradiol in YAZ is complexed with B-cyclodextrin as the EE-B-cyclodextrin clathrate to ensure shelf stability at low concentrations. No new toxicology studies were requested or submitted for NDA 21-873.

Labeling for YAZ is similar to that for approval of NDA 21-098 for Yasmin.

Reviewer: Krishan L. Raheja, D.V.M., Ph.D.

Through P/T Supervisor: Lynnda Reid, Ph.D.

Regulatory action: Based on review and approval of NDA 21-098 for Yasmin, Pharmacology recommends approval of NDA 21-873 for YAZ.

APPEARS THIS WAY
ON ORIGINAL

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Krishan L. Raheja
5/19/2006 01:17:59 PM
PHARMACOLOGIST

Lynnda Reid
5/19/2006 02:46:41 PM
PHARMACOLOGIST



DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

PHARMACOLOGY/TOXICOLOGY REVIEW AND EVALUATION

NDA NUMBER: 21873
SERIAL NUMBER: 000
DATE RECEIVED BY CENTER: 12/23/04
PRODUCT: Yaz (drospirenone 3 mg/ethinyl estradiol 0.02 mg)
INTENDED CLINICAL POPULATION: Contraceptive and PMDD
SPONSOR: Berlex Pharmaceuticals, Inc.
DOCUMENTS REVIEWED: Nonclinical Pharmacology and Toxicology, Section 5
(Electronic File: pharmtox\pharmtox.pdf)
REVIEW DIVISION: Division of Reproductive and Urologic Drug
Products (HFD- 580)
PHARM/TOX REVIEWER: Krishan L. Raheja, D.V.M., Ph.D.
PHARM/TOX SUPERVISOR: Lynnda Reid, Ph.D.
DIVISION DIRECTOR: Dan Shames, M.D.
PROJECT MANAGER: Charlene Williamson

Date of review submission to Division File System (DFS): 2-24-05

TABLE OF CONTENTS

EXECUTIVE SUMMARY	3
2.6 PHARMACOLOGY/TOXICOLOGY REVIEW	4
2.6.1 INTRODUCTION AND DRUG HISTORY	4
2.6.2 PHARMACOLOGY.....	5
2.6.3 PHARMACOLOGY TABULATED SUMMARY	5
2.6.4 PHARMACOKINETICS/TOXICOKINETICS.....	5
2.6.5 PHARMACOKINETICS TABULATED SUMMARY.....	5
2.6.6 TOXICOLOGY.....	5
2.6.7 TOXICOLOGY TABULATED SUMMARY.....	5
OVERALL CONCLUSIONS AND RECOMMENDATIONS.....	5
APPENDIX/ATTACHMENTS	6

EXECUTIVE SUMMARY

I. Recommendations

A. **Recommendation on approvability:** This NDA is similar in composition and indication to the sponsor's NDA 21-676 (YAZ containing drospirenone 3 mg/ethinyl estradiol 0.02 mg tablets) and NDA 21-098 (Yasmin containing 0.3 mg drospirenone/0.03 mg ethinyl estradiol tablets), both approved for oral contraception. Under NDA 21-873 the sponsor has evaluated YAZ for the treatment of premenopausal dysphoric disorder (PMDD).

Based on the similarity in composition and intended treatment populations with the sponsor's previously approved products, Pharmacology recommends approval of NDA 21-873.

B. **Recommendations for nonclinical studies:** None

C. **Recommendations on labeling:** Labeling will be similar to that for NDAs 21-098 and 21-676.

II. Summary of nonclinical findings

A. Brief overview of nonclinical findings: Nonclinical pharmacology and toxicology studies are referenced to NDA 21-098 and NDA 21-676, which are approved for similar indications. As such referenced studies are acceptable to support NDA 21-873.

B. Pharmacologic activity : Drospirenone has mainly progestogenic, antiandrogenic and antimineralocorticoid activity.

C. Nonclinical safety issues relevant to clinical use: none

**APPEARS THIS WAY
ON ORIGINAL**

2.6 PHARMACOLOGY/TOXICOLOGY REVIEW

2.6.1 INTRODUCTION AND DRUG HISTORY

NDA number: 21-873

Review number: 1

Sequence number/date/type of submission: 000/12-23-04

Information to sponsor: Yes () No (*)

Sponsor and/or agent: Berlex Laboratories, Inc. P.O.Box 1000, Montville, NJ 07045

Manufacturer for drug substance: Schering GmbH and Co. Germany

Reviewer name: Krishan L. Raheja, D.V.M., Ph.D.

Division name: Reproductive and Urologic Drug Products

HFD #: 580

Review completion date:

Drug:

Trade name: YAZ

Generic name: drospirenone (DRSP) 3 mg/ethinyl estradiol (EE) 0.02 mg tablets

Code name: ZK 30595 (drospirenone) ZK 4944 (ethinyl estradiol)

Chemical name: DRSP = (6B, 7B; 15B-dimethylene-3-oxo-17a-pregn-4-ene-21-17-carbolactone (IUPAC)

EE= 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol,(17a)

CAS registry number: 67392-87-4 (DRSP); 57-63-6 (EE)

Molecular formula/molecular weight: C₂₄H₃₀O₃/366.5 (DRSP); C₂₀H₂₄O₂/296.4 (EE)

Structure: Referred to NDA 21-098

Relevant INDs/NDAs/DMFs: IND 51,693; DMF 12138 (DRSP) and DMF 1985 (EE); NDA 21-098 (Yasmin) and NDA 21-676 (YAZ).

Drug class: DRSP (progestin); EE (estrogen)

Intended clinical population: as contraceptive and for PMDD

PMDD (premenopausal dysphoric disorder) is described as a distinct clinical entity with clear onset and offset of symptoms closely linked to the menstrual cycle and prominence of emotional symptoms.

Clinical formulation: tablets with composition as under NDA 21-676

Route of administration: oral

Disclaimer: Tabular and graphical information are constructed by the reviewer unless cited otherwise.

Data reliance: Except as specifically identified below, all data and information discussed below and necessary for approval of NDA 21-873 are owned by Berlex Laboratories, Inc. or are data for which Berlex Laboratories, Inc. has obtained a written right of reference. Any information or data necessary for approval of NDA 21-873 that Berlex Laboratories, Inc. does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as described in the drug's approved labeling. Any data or information described or referenced below from a previously approved application that Berlex Laboratories, Inc. does not own (or from FDA reviews or summaries of a previously approved application) is for descriptive purposes only and is not relied upon for approval of NDA 21-873.

Studies reviewed within this submission: None. All nonclinical studies are referenced to NDAs 21-098 and 21-676

Studies not reviewed within this submission: -

2.6.2 PHARMACOLOGY

Drospirenone is progestational agent with antiandrogenic and antimineralocorticoid activity. Drospirenone in combination with ethinyl estradiol acts by suppression of gonadotropins. Although the primary mechanism of action is inhibition of ovulation, other alterations include changes in cervical mucus (which increases the difficulty of sperm entry in to the uterus) and in the endometrium (which reduces the likelihood of implantation).

PHARMACOLOGY TABULATED SUMMARY: **none submitted**

2.6.3 PHARMACOKINETICS/TOXICOKINETICS

Referred to NDAs 21-098 and 21-676

2.6.5 PHARMACOKINETICS TABULATED SUMMARY

NONE SUBMITTED

2.6.6 TOXICOLOGY

All referred nonclinical studies were reviewed under NDAs 21-098 and 21-676

2.6.7 TOXICOLOGY TABULATED SUMMARY

NONE SUBMITTED

OVERALL CONCLUSIONS AND RECOMMENDATIONS

Conclusions: Based on the sponsor's approved NDAs 21-098 and 21-676 having the same composition and a similar intended population for NDA 21-873, Pharmacology has no safety concerns.

Unresolved toxicology issues (if any): None

Recommendations: Pharmacology recommends approval of NDA 21-873 for contraception and PMDD indications.

Suggested labeling: Labeling will be similar to that for NDAs 21-098 and 21-676

APPENDIX/ATTACHMENTS: NONE

APPEARS THIS WAY ON ORIGINAL

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Krishan L. Raheja
2/24/05 10:36:01 AM
PHARMACOLOGIST

Lynnda Reid
3/1/05 07:14:07 PM
PHARMACOLOGIST